Advise the patient to read the FDA-approved patient labeling (
Medication Guide
).
Storage and Disposal
Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store FIORINAL with CODEINE securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home [see Warnings and Precautions (
5.1
,
5.2
), Drug Abuse and Dependence (
9.2
)]. Inform patients that leaving FIORINAL with CODEINE unsecured can pose a deadly risk to others in the home.
Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines. If no take back programs or DEA-registered collectors are available, instruct patients to dispose of FIORINAL with CODEINE by following these four steps:
- Mix FIORINAL with CODEINE (do not crush) with an unpalatable substance such as dirt, cat litter, or used coffee grounds;
- Place the mixture in a container such as a sealed plastic bag;
- Throw the container in the household trash;
- Delete all personal information on the prescription label of the empty bottle
- How to treat naloxone in the event of an opioid overdose
- To tell family and friends about their naloxone and to keep it in a place where family and friends can access it in an emergency
- To read the Patient Information (or other educational material) that will come with their naloxone. Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do.
Inform patients that they can visit
www.fda.gov/drugdisposal for additional information on disposal of unused medicines.
Addiction, Abuse, and Misuse
Inform patients that the use of FIORINAL with CODEINE, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see Warnings and Precautions (
5.1
)
]
. Instruct patients not to share FIORINAL with CODEINE with others and to take steps to protect FIORINAL with CODEINE from theft or misuse.
Life-Threatening Respiratory Depression
Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting FIORINAL with CODEINE or when the dosage is increased, and that it can occur even at recommended dosages.
Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see Warnings and Precautions (
5.3
)].
Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose
Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with FIORINAL with CODEINE. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see Dosage and Administration (
2.2
), Warnings and Precautions (
5.3
)].
Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.
Explain to patients and caregivers that naloxone’s effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered [see Overdosage (
10
)].
If naloxone is prescribed, also advise patients and caregivers:
Accidental Ingestion
Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death.
Risks from Concomitant Use with Benzodiazepines and Other CNS Depressants
Inform patients and caregivers that potentially fatal additive effects may occur if FIORINAL with CODEINE is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider [see Warnings and Precautions (5.4), Drug Interactions (7)].
Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-threatening Respiratory Depression in Children
Advise caregivers that FIORINAL with CODEINE is contraindicated in all children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Advise caregivers of children 12-18 years of age receiving FIORINAL with CODEINE to monitor for signs of respiratory depression [see Warnings and Precautions (
5.5
)].
Serotonin Syndrome
Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take serotonergic medications [see
Drug Interactions (
7
)
].
MAOI Interaction
Inform patients not to take FIORINAL with CODEINE while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking FIORINAL with CODEINE [see Drug Interactions (7)].
Adrenal Insufficiency
Inform patients that opioids could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [s
e
e Warnings and Precautions (
5.10
)
].
Important Administration Instructions
Instruct patients how to properly take FIORINAL with CODEINE [see Dosage and Administration (2.3)]. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.
Important Discontinuation Instructions
In order to avoid developing withdrawal symptoms, instruct patients not to discontinue FIORINAL with CODEINE without first discussing a tapering plan with the prescriber [see Dosage and Administration (
2.4
)].
Hypotension
Inform patients that FIORINAL with CODEINE may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see Warnings and Precautions
(
5.11
)
].
Anaphylaxis
Inform patients that anaphylaxis has been reported with ingredients contained in FIORINAL with CODEINE. Advise patients how to recognize such a reaction and when to seek medical attention [see Contraindications (
4
)
, Adverse Reactions (
6
)
]
.
Serious Skin Reactions, including DRESS
Advise patients to stop taking FIORINAL with CODEINE immediately if they develop any type of rash or fever and to contact their healthcare provider as soon as possible [
see Warnings and Precautions (
5.20
)
].
Aspirin Allergy
Patients should be informed that FIORINAL with CODEINE contains aspirin and should not be taken by patients with an aspirin or NSAIDs allergy [see Warnings and
Precautions (
5.21
)].
Pregnancy
Neonatal Opioid Withdrawal Syndrome
Inform female patients of reproductive potential that prolonged use of FIORINAL with CODEINE during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see Warnings and
Precautions (
5.6
), Use in
Specific Populations (
8.1
)
]
.
Embryo-Fetal Toxicity
Inform female patients of reproductive potential that FIORINAL with CODEINE can (or may) cause fetal harm and to inform the healthcare provider of a known or suspected pregnancy. Inform pregnant women to avoid use of aspirin and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus. If treatment with FIORINAL with CODEINE is needed for a pregnant woman between about 20 to 30 weeks gestation, advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours [see Warnings and Precautions (
5.16
) and Use in Specific Populations (
8.1
)].
Lactation
Advise women that breastfeeding is not recommended during treatment with FIORINAL with CODEINE [see Use in Specific Populations
(
8.2
)
].
Infertility
Inform patients that chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible [see Use in Specific Populations (8.3)].
Risk of Bleeding
Inform patients about the signs and symptoms of bleeding. Tell patients to notify their physician if they are prescribed any drug which may increase risk of bleeding.
Counsel patients who consume three or more alcoholic drinks daily about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin [see Warnings and Precautions (
5.18
)].
Driving or Operating Heavy Machinery
Inform patients that FIORINAL with CODEINE may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication [see Warnings and Precautions (
5.17
)
].
Constipation
Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see
A
dverse Reactions (
6
)
].
Distributed by:
Allergan USA, Inc.
Madison, NJ 07940
©2021 Allergan. All rights reserved.
FIORINAL® is a registered trademark of Allergan Sales, LLC.
All trademarks are the property of their respective owners.
Revised: April 2021
v3.0USPI6010